Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COSTEM 2019 | BCMA-specific CAR-T cells for R/R multiple myeloma

Nicolaus Kröger • 25 Oct 2019
COSTEM 2019
Multiple Myeloma CAR-T

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, evaluates the efficacy and safety of B-cell maturation antigen-specific (BCMA) CAR-T cells for relapsed/refractory multiple myeloma. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Nicolaus Kröger

COSTEM 2023: congress highlights and importance
1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
The importance of bridging therapy in follicular and mantle cell lymphoma
0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
CAR-T therapy versus autoSCT in DLBCL
1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
The need for disease-modifying drugs in myelofibrosis
0:51
The need for disease-modifying drugs in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Nicolaus Kröger • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Nicolaus Kröger • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Nicolaus Kröger • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Nicolaus Kröger • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals